http://www.pharmaasia.comPharmaAsia - Regulatory and Legalen-USCopyright 2012 Ten Alps Communications Asia. All rights reserved.Thu, 9 Feb 2012 19:21:44 +0800http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322MabCure has signed a license agreement with Biotech Investment Corp. (Biotech), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15 percent of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5 percent on revenues.http://www.pharmaasia.com/article/mabcure-signs-license-agreement-with-biotech-investment-corp/9322Tue, 7 Feb 2012 00:00:00 +0800http://www.pharmaasia.com/article/drug-process-licensing-associates-launches-pharma-database/9308PHILL, which stands for PHarmaceutical InteLLigence, is a database of bulk drug and intermediates producer information pertinent to members of the chemical and pharmaceutical industry. It also includes regulatory information such as Drug Master Files, Veterinary Master Files, Certificates of Suitability and Drug Approvals.http://www.pharmaasia.com/article/drug-process-licensing-associates-launches-pharma-database/9308Fri, 27 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/merck-appoints-heads-of-corporate-auditing-corporate-strategy/9297Merck announced that Friederike Rotsch has been appointed head of corporate auditing. She reports to Karl-Ludwig Kley, chairman of the executive board of Merck. At the same time, the company announced that Isabel De Paoli will assume the leadership of corporate strategy. She too will report directly to Kley.http://www.pharmaasia.com/article/merck-appoints-heads-of-corporate-auditing-corporate-strategy/9297Tue, 10 Jan 2012 00:00:00 +0800http://www.pharmaasia.com/article/biogen-idec-and-elan-receive-notification-of-pdufa-date-extension/9257Biogen Idec and Elan are working with the FDA to help facilitate a timely review of the REMS changes and the sBLA.http://www.pharmaasia.com/article/biogen-idec-and-elan-receive-notification-of-pdufa-date-extension/9257Thu, 20 Oct 2011 00:00:00 +0800http://www.pharmaasia.com/article/beigene-in-licenses-two-clinical-stage-oncology-compounds/9246BeiGene will collaborate with Janssen in phase III clinical trials in melanoma and explore additional solid tumor indications in solid tumors prevalent in China and Asia.http://www.pharmaasia.com/article/beigene-in-licenses-two-clinical-stage-oncology-compounds/9246Sat, 15 Oct 2011 00:00:00 +0800http://www.pharmaasia.com/article/victoza-now-available-to-people-with-type-2-diabetes-in-china/9236Approved by the Chinese State Food and Drug Administration (SFDA) on 15 March 2011.http://www.pharmaasia.com/article/victoza-now-available-to-people-with-type-2-diabetes-in-china/9236Mon, 10 Oct 2011 00:00:00 +0800http://www.pharmaasia.com/article/nycomed-and-almirall-announce-a-licensing-agreement-for-ebastine-in-china-and-other-key-southeast-asia-markets/9230• With this agreement, Almirall extends the global reach of the product, present now in more than 30 countries worldwide.http://www.pharmaasia.com/article/nycomed-and-almirall-announce-a-licensing-agreement-for-ebastine-in-china-and-other-key-southeast-asia-markets/9230Thu, 29 Sep 2011 00:00:00 +0800http://www.pharmaasia.com/article/novartis-receives-approval-in-japan-for-two-innovative-therapies/9226Approvals demonstrate ongoing Novartis commitment to bringing innovative treatments to patients in Japan.http://www.pharmaasia.com/article/novartis-receives-approval-in-japan-for-two-innovative-therapies/9226Tue, 27 Sep 2011 00:00:00 +0800http://www.pharmaasia.com/article/astrazeneca-announces-first-approval-of-faslodex-in-japan/9228In Japan, it is estimated that annually 10,000 women with metastatic breast cancer will have their cancer recurring or progressing post endocrine therapy.http://www.pharmaasia.com/article/astrazeneca-announces-first-approval-of-faslodex-in-japan/9228Mon, 26 Sep 2011 00:00:00 +0800http://www.pharmaasia.com/article/sanofi-pasteur-acquires-exclusive-worldwide-license-for-acne-vaccine-and-treatment/9224Pre-clinical vaccine was developed by researchers at the University of California, San Diego.http://www.pharmaasia.com/article/sanofi-pasteur-acquires-exclusive-worldwide-license-for-acne-vaccine-and-treatment/9224Wed, 21 Sep 2011 00:00:00 +0800